Please login to the form below

Not currently logged in
Email:
Password:

Norgine increases ProStrakan stake

Norgine has increased its stake in Scotland-based biotech ProStrakan sparking speculation that it could be to set to make a counter bid to KHK

Dutch company Norgine has raised its stake in ProStrakan to 14 per cent, which could cause Kyowa Hakko Kirin's (KHK) £292m takeover plans to falter.

At the time of writing, shares in ProStrakan stood at 132.38p, above the 130p-a-share bid agreed with the Japanese firm earlier in the week, boosted by the prospect that Norgine could be about to make a higher bid.

In mid-November, ProStrakan refused an offer from Norgine, which purchased a 13.75 per cent stake, because it was said to have undervalued the company. The Dutch company said at the time that it had "no current intention" to mount a full-scale takeover bid.

ProStrakan has a number of products in key global markets including Sancuso (granisetron transdermal), a novel skin patch for the prevention of chemotherapy-induced nausea and vomiting, and cancer pain treatment Abstral (fentanyl).

24th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics